2026-03-03 - MDT - Medtronic Deep Dive

Article published Mar 3, 2026. Prices below use latest available snapshots.

MDT Price Structure

Loading chart…

Loading timeframes…

Conviction: Medium Status: Watching — RSI 36.3 (data as of 02/23), approaching entry zone, price ~$98.61

Quick Snapshot

Signal	Reading
Overall	🟡 RSI 36.3 (last OHLC: 02/23) — approaching oversold. Price $98.61, +2.3% in 7 days, -2.0% in 30 days. SMA20 $100.61. Near SMA. Alert at $92 still active.
Moat	Moderate-Wide — scale and switching costs, but execution has lagged peers
Key insight	MDT data stale (last entry 02/23). The 7D improved to +2.3% from +1.8% (last read), suggesting a slight upward bounce. RSI at 36.3 is still above the 30-35 entry zone. Need RSI to drop to 30-35 WITH price in $88-94 zone for ideal entry. Currently not in that zone.

Action Matrix

Action	Level	Why
Current	🔍 Watch	RSI 36.3 approaching entry zone but price not yet at ideal $88-94. Alert at $92.
Entry Zone	$88 - $94	~10-15% pullback from current ~$98; prior support zone
Stop-Loss	$79 (-20%)	Below 52-week low ($79.55) — thesis-killer territory
Target 1	$108 (+10%)	Return to consensus analyst target zone
Target 2	$117 (+19%)	All-time high (Sept 2021) — full recovery scenario

Extended analysis

Price Data

Stock	Price	1D	7D	30D	3M	52wkHi	RSI	Status	Action
MDT	$98.61	+1.8%	+2.3%	-2.0%	—	-4.4%	36	🟡 Approaching Oversold	🔍 Watch

Note: OHLC data last updated 2026-02-23. RSI 36.3, SMA20 $100.61.

Price vs Last Deep Dive (02/26)

Metric	02/26	03/03	Change
Price	$98.61	$98.61	$0.00 (data stale since 02/23)
RSI	36.3	36.3	0.0 (stale)
SMA20	$100.61	$100.61	Unchanged (stale)
vs SMA	-2.0%	-2.0%	Stale

Update (03/03): MDT OHLC data has not refreshed since 02/23. The 7D reading (+2.3% vs prior +2.4% on 02/26 file) shows effectively no change from stale data. RSI at 36.3 still above the 30-35 entry trigger. Price at $98.61 is still above the $88-94 entry zone. No change in action or analysis.

Company Overview

One-Liner

Medtronic is the world's largest standalone medical device company by revenue — a $34B/year enterprise spanning heart rhythm management, surgical robotics, spinal implants, neurostimulation, and diabetes technology operating in 150+ countries.

Business Model

Question	Answer
What they sell	Implantable and non-implantable medical devices, capital equipment, disposables, software systems
Who pays	Hospitals, health systems, surgical centers, government payers
Revenue model	Mix of capital equipment (upfront) + high-margin disposables/consumables (recurring), service contracts
How sticky	High — physician training on specific platforms creates lock-in; hospital systems make multi-year purchasing commitments

Key Segments (Q3 FY2026 — Quarter Ended January 23, 2026)

Segment	Q3 Revenue	Q3 Organic Growth	Key Products	Notes
Cardiovascular	$3.457B	+10.6%	PFA/Affera system, TAVR (Evolut), cardiac monitoring	Star segment — PFA +80% global, +137% US
Neuroscience	$2.558B	+2.5%	Spinal fusion/implants, neuro-stimulation, ENT	Slowest growth
Medical Surgical	$2.173B	+2.7%	Hugo surgical robot, endoscopy	Hugo FDA cleared Feb 2026 — early innings
Diabetes	$796M	+8.3%	MiniMed CGM, insulin pumps	Being spun off as MiniMed (mid-late 2026)

Investment Thesis

Bull Case — The Inflection Is Real

Argument	Evidence	Conviction
PFA is a genuine multi-year growth driver	Cardiac Ablation Solutions +80% global, +137% US in Q3 FY26.	🟢 High
MiniMed spinoff unlocks value and focus	Removing GLP-1 narrative overhang; 100+ bps margin uplift post-spinoff.	🟢 High
Hugo FDA clearance opens $13B+ robot market	Just cleared for urologic procedures Feb 2026.	🟡 Medium (early)
Dividend aristocrat with 48 years of increases	$2.84/year annual dividend (~2.9% yield at current price).	🟢 High
Valuation is modest vs. peer group	MDT P/E ~26x forward — cheapest large-cap medtech. BSX at 57x. SYK at ~35x.	🟢 Medium-High

Bear Case — The Value Trap Scenario

Argument	Evidence	Risk Level
10-year history of underperformance	MDT all-time high was Sept 2021 ($117.57). Still 16% below that.	🟠 Real
Hugo is years from meaningful revenue	ISRG has 10,763+ installed systems. Hugo just got first FDA clearance Feb 2026.	🟠 Real
Neuroscience / Spine is a structural drag	Spine market mature, price-deflationary.	🟡 Medium

Technical Setup

Indicator	Value	Signal
Price	$98.61	Still above entry zone
RSI (14)	36.3 (last valid: 02/23)	🟡 Approaching Oversold — not yet at entry trigger
SMA20	$100.61	Price -2.0% below SMA — very close
52-week range	$79.55 - $103.18	Near top of range
YTD performance	~+22%	Significant outperformance YTD

Key Technical Levels

Level	Price	Notes
Immediate support	$93-95	Post-Q3 earnings gap-up base
Entry zone	$88-94	RSI trigger + price target together
Strong support	$79-82	52-week low zone
Resistance 1	$100.61	SMA20 — just above
Resistance 2	$103.18	52-week high in data window
Long-term target	$108-117	Analyst consensus ($111.77 avg) to ATH recovery

Catalysts & Timing

Date	Event	Impact	Watch For
Mid-2026	MiniMed Diabetes spinoff/IPO	🟢🟢	Removes GLP-1 narrative; potential value unlock
Q4 FY26 Earnings (~May 2026)	Final quarter before FY26 close	🟢	Whether organic growth stays 5.5%+
FY2026-FY2027	Hugo US commercial placements	🟢	First disclosed Hugo placement/revenue data
Ongoing	PFA (Affera) market share vs BSX	🟢	Can MDT sustain majority share in new EP labs?

Entry Strategy

Strategy	Details
Current	Watch — RSI approaching 35, price still above entry zone
Alert	$92 — entry zone bottom
Entry zone	$88 - $94 (~10-15% pullback)
RSI target	RSI < 35 with price in $88-94 zone
Stop	$79 (-20% from entry zone)

Research Log

Date	Update
2026-02-22	Created deep dive. MDT not in stonks data system. Price ~$97.58 (market data). RSI ~58 (estimated). Q3 FY26 showed strongest enterprise growth in 10 quarters (+6.0% organic). PFA franchise +80%. Hugo FDA cleared for urology Feb 2026. Conviction: Medium. Action: Watch, alert at $92.
2026-02-26	Fresh OHLC data now available. Price $98.61 (+1.1% vs prior). RSI fresh at 36.3. SMA20 $100.61. RSI drop from ~58 to 36.3 shows post-Q3 digestion underway. -2.4% 7D, -2.0% 30D. Getting closer to entry zone but not there yet. Action: Watch, maintain $92 alert.
2026-03-03	OHLC data stale since 02/23. No change in data. 7D +2.3% (marginal improvement). RSI 36.3, price $98.61 above entry zone. Action unchanged: Watch, $92 alert active.

The Gold

Key Discoveries

Discovery	Implication
RSI dropped from ~58 to 36.3	Post-Q3 enthusiasm cooling — approaching entry territory
SMA20 $100.61, price $98.61 (only -2% gap)	Right at moving average — clean technical level
52wk high $103.18 only 4.4% above	Upside is toward analyst targets ($108-117)
+2.3% 7D with RSI at 36	Price holding while RSI declined — constructive

Open Questions

Is RSI still 36.3 or has it moved toward entry zone?
What are the specific Hugo US placement numbers from Q3 FY26 earnings call?
Is Affera genuinely winning majority share in new EP lab openings?
What multiple will MiniMed trade at post-spinoff?

Mistakes (If Applicable)

Mistake	Lesson
N/A — first deep dive, no capital deployed	Wait for pullback to $88-94 — RSI at 36 is better than 58 but entry zone is still below current price

Sources

Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.